BS_3V3KE3VT
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 3.4799999999999995
- os_event
- false
- age_years
- 3.926
- sex
- F
- race
- White
- e1_e2
- E1
- umap1_2d
- -4.483564276
- umap2_2d
- 2.489696275
- umap1_3d
- -2.538132034
- umap2_3d
- 2.654475156
- umap3_3d
- -1.10696836
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.460
- NOTCH_SIGNALING+0.410
- APICAL_SURFACE+0.370
- KRAS_SIGNALING_DN+0.280
- ANGIOGENESIS+0.250
- CHOLESTEROL_HOMEOSTASIS+0.210
- ESTROGEN_RESPONSE_LATE+0.190
- SPERMATOGENESIS+0.190
- MYC_TARGETS_V1+0.180
Top 10 suppressed
- PROTEIN_SECRETION-0.490
- OXIDATIVE_PHOSPHORYLATION-0.390
- TGF_BETA_SIGNALING-0.290
- ADIPOGENESIS-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- PEROXISOME-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.240
- HEME_METABOLISM-0.230
- APOPTOSIS-0.220
- ANDROGEN_RESPONSE-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0374 | Med | Medulloblastoma | 0.680 |
| 2 | s_150324_2a | EPN | Supratentorial EPN | 0.680 |
| 3 | C3L-02964 | — | cohortSQ1 | 0.676 |
| 4 | 83486 | EPN | Supratentorial EPN | 0.665 |
| 5 | BS_3MS8WVNR | high-grade glioma | — | 0.654 |
| 6 | BS_RCCN63K6 | high-grade glioma | — | 0.650 |
| 7 | BS_WJ9H4NZZ | high-grade glioma | — | 0.638 |
| 8 | SRR8613784 | — | E | 0.637 |
| 9 | MNG155 | — | — | 0.628 |
| 10 | C3N-02282 | — | cohortSQ1 | 0.622 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.410 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.370 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |